• Alias: ZD 1839
    • Inhibits the catalytic activity of numerous RTKs, including the EGFR
    • FDA approved for locally advanced or metastatic NSCLC for those who have benefited from gefitinib in the past, for those benefiting presently, or for those on clinical trial
    • Recommended dose: 250 mg orally once daily with or without food; may dissolve in noncarbonated water if the tablet cannot be swallowed
    • Half-life: 48 hours
    • Metabolism: Major CYP3A4 substrate
    • Common side effects: Skin rash (dry skin), nausea/vomiting, diarrhea, anorexia, pruritus
    Other topics in Targeted and Immunotherapy Agents